Annual CFO
-$62.60 M
-$10.54 M-20.23%
December 31, 2024
Summary
- As of March 10, 2025, JSPR annual cash flow from operations is -$62.60 million, with the most recent change of -$10.54 million (-20.23%) on December 31, 2024.
- During the last 3 years, JSPR annual CFO has fallen by -$28.92 million (-85.88%).
- JSPR annual CFO is now -242.71% below its all-time high of -$18.27 million, reached on December 31, 2020.
Performance
JSPR Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$21.13 M
-$7.08 M-50.40%
December 31, 2024
Summary
- As of March 10, 2025, JSPR quarterly cash flow from operations is -$21.13 million, with the most recent change of -$7.08 million (-50.40%) on December 31, 2024.
- Over the past year, JSPR quarterly CFO has stayed the same.
- JSPR quarterly CFO is now -264.95% below its all-time high of -$5.79 million, reached on June 30, 2021.
Performance
JSPR Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$62.60 M
-$4.66 M-8.03%
December 31, 2024
Summary
- As of March 10, 2025, JSPR TTM cash flow from operations is -$62.60 million, with the most recent change of -$4.66 million (-8.03%) on December 31, 2024.
- Over the past year, JSPR TTM CFO has stayed the same.
- JSPR TTM CFO is now -910.52% below its all-time high of -$6.20 million, reached on March 31, 2021.
Performance
JSPR TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
JSPR Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -20.2% | 0.0% | 0.0% |
| 3 y3 years | -85.9% | -76.4% | -29.8% |
| 5 y5 years | -242.7% | -76.4% | -29.8% |
JSPR Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -85.9% | at low | -125.9% | at low | -85.9% | at low |
| 5 y | 5-year | -242.7% | at low | -264.9% | at low | -910.5% | at low |
| alltime | all time | -242.7% | at low | -264.9% | at low | -910.5% | at low |
Jasper Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$62.60 M(+20.2%) | -$21.13 M(+50.4%) | -$62.60 M(+8.0%) |
| Sep 2024 | - | -$14.05 M(+20.3%) | -$57.95 M(+3.7%) |
| Jun 2024 | - | -$11.68 M(-25.8%) | -$55.88 M(-2.8%) |
| Mar 2024 | - | -$15.74 M(-4.5%) | -$57.47 M(+10.4%) |
| Dec 2023 | -$52.07 M(+13.5%) | -$16.48 M(+37.5%) | -$52.07 M(+7.9%) |
| Sep 2023 | - | -$11.98 M(-9.7%) | -$48.23 M(+5.1%) |
| Jun 2023 | - | -$13.27 M(+28.4%) | -$45.90 M(+9.3%) |
| Mar 2023 | - | -$10.34 M(-18.3%) | -$41.98 M(-8.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2022 | -$45.86 M(+36.2%) | -$12.65 M(+31.1%) | -$45.86 M(-4.1%) |
| Sep 2022 | - | -$9.64 M(+3.1%) | -$47.80 M(+5.6%) |
| Jun 2022 | - | -$9.36 M(-34.2%) | -$45.26 M(+8.5%) |
| Mar 2022 | - | -$14.21 M(-2.5%) | -$41.70 M(+23.8%) |
| Dec 2021 | -$33.68 M(+84.4%) | -$14.58 M(+105.2%) | -$33.68 M(+76.4%) |
| Sep 2021 | - | -$7.11 M(+22.7%) | -$19.09 M(+59.3%) |
| Jun 2021 | - | -$5.79 M(-6.5%) | -$11.99 M(+93.5%) |
| Mar 2021 | - | -$6.20 M | -$6.20 M |
| Dec 2020 | -$18.27 M | - | - |
FAQ
- What is Jasper Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Jasper Therapeutics?
- What is Jasper Therapeutics annual CFO year-on-year change?
- What is Jasper Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Jasper Therapeutics?
- What is Jasper Therapeutics quarterly CFO year-on-year change?
- What is Jasper Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Jasper Therapeutics?
- What is Jasper Therapeutics TTM CFO year-on-year change?
What is Jasper Therapeutics annual cash flow from operations?
The current annual CFO of JSPR is -$62.60 M
What is the all time high annual CFO for Jasper Therapeutics?
Jasper Therapeutics all-time high annual cash flow from operations is -$18.27 M
What is Jasper Therapeutics annual CFO year-on-year change?
Over the past year, JSPR annual cash flow from operations has changed by -$10.54 M (-20.23%)
What is Jasper Therapeutics quarterly cash flow from operations?
The current quarterly CFO of JSPR is -$21.13 M
What is the all time high quarterly CFO for Jasper Therapeutics?
Jasper Therapeutics all-time high quarterly cash flow from operations is -$5.79 M
What is Jasper Therapeutics quarterly CFO year-on-year change?
Over the past year, JSPR quarterly cash flow from operations has changed by $0.00 (0.00%)
What is Jasper Therapeutics TTM cash flow from operations?
The current TTM CFO of JSPR is -$62.60 M
What is the all time high TTM CFO for Jasper Therapeutics?
Jasper Therapeutics all-time high TTM cash flow from operations is -$6.20 M
What is Jasper Therapeutics TTM CFO year-on-year change?
Over the past year, JSPR TTM cash flow from operations has changed by $0.00 (0.00%)